Journal: Glia

Article Title: Involvement of placental growth factor in Wallerian degeneration.

doi: 10.1002/glia.21108

Figure Lengend Snippet: Fig. 1. Confirmation of PlGF Ab specificity. (A) PlGF immunostaining on transverse section of sci- atic nerve. (B) Negative control: nerve section stained with anti-PlGF Ab preincubated with its spe- cific blocking peptide. (C) PlGF immunostaining on placenta used as positive control tissue and (D) on liver used as negative control tissue. Scale bar: 60lm.

Article Snippet: To characterize PlGF expression, double immunofluorescenct stainings for PlGF (sc-27134; 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, Taylor and Goldenberg, 2007) and NF-H (MAB5448/clone TA51; 1:500; Millipore, De Girolamo et al., 2000) for axons, Neu-N (MAB377/ clone A60; 1:250; Millipore, Borsani et al., 2010) for neuronal cell nuclei, S100 (ZO311; 1/200; DakoCytomation, Gould et al., 1986) for quiescent SCs, p75NGFr (AB1554; 1/200; Millipore, Runyan and Phelps, 2009) for proliferating SCs, von Willebrand factor (vWF; AB6994; 1/2000; Abcam, Yin et al., 2010) for endothelial cells, patched-1 (Ptc-1; sc-9016/H-267; 1/50; Santa Cruz Biotechnology, Chen et al., 2007) for fibroblasts, CD11b (MCA74; 1/250; Serotec, Springer et al., 1979) for macrophages, P0 (AB9352; 1/50; Millipore) for peripheral myelin, were performed.

Techniques: Immunostaining, Negative Control, Staining, Blocking Assay, Positive Control

Journal: Glia

Article Title: Involvement of placental growth factor in Wallerian degeneration.

doi: 10.1002/glia.21108

Figure Lengend Snippet: Fig. 12. Functional recovery. (A) Representative footprints obtained from wt and Pgf 2/2 mice, 21 days after unilateral left sciatic nerve transection. Measures of the length of the operated footprints (OPL) and the normal footprints (NPL) were used to calculate the print-length factor (PLF). (B) Graph showing the recovery of motor function after sciatic nerve transection determined by the PLF (described in the Methods section). Worse recovery is evident in mice lacking PlGF com- pared with their wt controls.

Article Snippet: To characterize PlGF expression, double immunofluorescenct stainings for PlGF (sc-27134; 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, Taylor and Goldenberg, 2007) and NF-H (MAB5448/clone TA51; 1:500; Millipore, De Girolamo et al., 2000) for axons, Neu-N (MAB377/ clone A60; 1:250; Millipore, Borsani et al., 2010) for neuronal cell nuclei, S100 (ZO311; 1/200; DakoCytomation, Gould et al., 1986) for quiescent SCs, p75NGFr (AB1554; 1/200; Millipore, Runyan and Phelps, 2009) for proliferating SCs, von Willebrand factor (vWF; AB6994; 1/2000; Abcam, Yin et al., 2010) for endothelial cells, patched-1 (Ptc-1; sc-9016/H-267; 1/50; Santa Cruz Biotechnology, Chen et al., 2007) for fibroblasts, CD11b (MCA74; 1/250; Serotec, Springer et al., 1979) for macrophages, P0 (AB9352; 1/50; Millipore) for peripheral myelin, were performed.

Techniques: Functional Assay

Journal: Glia

Article Title: Involvement of placental growth factor in Wallerian degeneration.

doi: 10.1002/glia.21108

Figure Lengend Snippet: Fig. 13. Model of PlGF function in the injured peripheral nerve. Fol- lowing axonal breakdown, the released PlGF can bind to its flt-1 recep- tor on SC, which in turn (i) produces PlGF and chemokines through the activation of the NF-jB signaling pathway, (ii) proliferate, and (iii) align to form bands of B€ungner, promoting axonal regeneration. PlGF also influences directly monocyte chemoattraction, thereby increasing macrophage activity of myelin debris phagocytosis, necessary to suc- cessful axonal regeneration.

Article Snippet: To characterize PlGF expression, double immunofluorescenct stainings for PlGF (sc-27134; 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, Taylor and Goldenberg, 2007) and NF-H (MAB5448/clone TA51; 1:500; Millipore, De Girolamo et al., 2000) for axons, Neu-N (MAB377/ clone A60; 1:250; Millipore, Borsani et al., 2010) for neuronal cell nuclei, S100 (ZO311; 1/200; DakoCytomation, Gould et al., 1986) for quiescent SCs, p75NGFr (AB1554; 1/200; Millipore, Runyan and Phelps, 2009) for proliferating SCs, von Willebrand factor (vWF; AB6994; 1/2000; Abcam, Yin et al., 2010) for endothelial cells, patched-1 (Ptc-1; sc-9016/H-267; 1/50; Santa Cruz Biotechnology, Chen et al., 2007) for fibroblasts, CD11b (MCA74; 1/250; Serotec, Springer et al., 1979) for macrophages, P0 (AB9352; 1/50; Millipore) for peripheral myelin, were performed.

Techniques: Activation Assay, Activity Assay